Abstract
In premature infants, effective and safe drug therapy depends on optimal dose selection and requires a thorough understanding of the underlying disease(s) of these fragile infants as well as the pharmacokinetics and pharmacodynamics of the drugs selected to treat their diseases. Differences in gestational and postnatal age or weight are the major determinants of the observed variability in drug disposition and effect in these infants. This article presents an outline on how to translate the results of a population pharmacokinetic/pharmacodynamic study into rational dosing regimens, and how physiologically based pharmacokinetic modeling, electronic health records, and the abundantly available data of vital functions of premature infants during their stay in the neonatal intensive care unit for evaluation of their pharmacotherapy can be used to tailor the most safe and effective dose in these infants.
| Original language | English |
|---|---|
| Pages (from-to) | S141-S151 |
| Journal | Journal of Clinical Pharmacology |
| Volume | 61 |
| Issue number | S1 |
| DOIs | |
| Publication status | Published - 29 Jun 2021 |
Bibliographical note
Funding Information:The authors received no financial support for the research, authorship, and/or publication of this article.
Publisher Copyright:
© 2021, The American College of Clinical Pharmacology
Fingerprint
Dive into the research topics of 'Considerations for Drug Dosing in Premature Infants'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver